Gareth J. Veal
About
Gareth J. Veal is a scholar working on Molecular Biology, Oncology and Pediatrics, Perinatology and Child Health.
According to data from OpenAlex, Gareth J. Veal has authored 136 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Molecular Biology, 42 papers in Oncology and 36 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Gareth J. Veal's work include Neuroblastoma Research and Treatments (28 papers), Cancer therapeutics and mechanisms (27 papers) and Acute Lymphoblastic Leukemia research (26 papers). Gareth J. Veal is often cited by papers focused on Neuroblastoma Research and Treatments (28 papers), Cancer therapeutics and mechanisms (27 papers) and Acute Lymphoblastic Leukemia research (26 papers). Gareth J. Veal collaborates with scholars based in United Kingdom, United States and Netherlands. Gareth J. Veal's co-authors include Alan V. Boddy, Étienne Chatelut, Christopher P.F. Redfern, Angélo Paci, David Back, Jane L. Armstrong, Michael Cole, Jos H. Beijnen, Christophe Bardin and Dominique Levêque and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Journal of Clinical Oncology.
In The Last Decade
Gareth J. Veal
127 papers receiving 3.6k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gareth J. Veal United Kingdom | 32 | 1.3k | 1.0k | 615 | 570 | 391 | 136 | 3.7k | ||
| John M. Kovarik Switzerland | 44 | 1.6k 1.2× | 1.0k 1.0× | 898 1.5× | 577 1.0× | 337 0.9× | 137 | 5.9k | ||
| Timothy W. Synold United States | 39 | 2.4k 1.8× | 2.3k 2.3× | 555 0.9× | 651 1.1× | 216 0.6× | 194 | 5.9k | ||
| Étienne Chatelut France | 43 | 1.8k 1.3× | 2.6k 2.6× | 755 1.2× | 1.0k 1.8× | 202 0.5× | 234 | 6.6k | ||
| Antonello Di Paolo Italy | 34 | 1.1k 0.9× | 1.4k 1.4× | 227 0.4× | 477 0.8× | 376 1.0× | 141 | 3.6k | ||
| Massimo Zucchetti Italy | 40 | 1.8k 1.4× | 1.9k 1.9× | 425 0.7× | 579 1.0× | 98 0.3× | 170 | 4.8k | ||
| Alan V. Boddy United Kingdom | 41 | 2.4k 1.9× | 2.2k 2.1× | 645 1.0× | 670 1.2× | 116 0.3× | 188 | 5.9k | ||
| Kristine R. Crews United States | 38 | 1.2k 0.9× | 920 0.9× | 1.7k 2.8× | 477 0.8× | 192 0.5× | 100 | 4.9k | ||
| Cristina Rodríguez‐Antona Spain | 39 | 2.2k 1.7× | 2.1k 2.0× | 369 0.6× | 767 1.3× | 178 0.5× | 137 | 6.0k | ||
| Lalitha Iyer United States | 25 | 2.4k 1.8× | 1.7k 1.7× | 598 1.0× | 294 0.5× | 292 0.7× | 52 | 4.0k | ||
| Bruno Lacarelle France | 35 | 951 0.7× | 1.2k 1.2× | 364 0.6× | 290 0.5× | 738 1.9× | 169 | 3.7k |
Countries citing papers authored by Gareth J. Veal
Since
Specialization
Citations
This map shows the geographic impact of Gareth J. Veal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gareth J. Veal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gareth J. Veal more than expected).
Fields of papers citing papers by Gareth J. Veal
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gareth J. Veal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gareth J. Veal. The network helps show where Gareth J. Veal may publish in the future.
Co-authorship network of co-authors of Gareth J. Veal
This figure shows the co-authorship network connecting the top 25 collaborators of Gareth J. Veal. A scholar is included among the top collaborators of Gareth J. Veal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gareth J. Veal. Gareth J. Veal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Blair, Helen J., Anthony V. Moorman, Olaf Heidenreich, et al.. (2024). Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia. Leukemia. 38(6). 1223–1235.
2.
Geller, James I., Martine van Grotel, Marc Ansari, et al.. (2024). Local application of sodium thiosulfate as an otoprotectant for cisplatin-exposed patients – A narrative literature review to explore the potential benefit for children with cancer. SHILAP Revista de lepidopterología. 5. 100211–100211.
3.
Ansari, Marc, Éric Bouffet, Archie Bleyer, et al.. (2024). Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature. Journal of Clinical Oncology. 42(18). 2219–2232.
4.
Lopez, Juanita, Julia Lai‐Kwon, R. Molife, et al.. (2023). A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma. British Journal of Cancer. 129(5). 811–818.
5.
Amant, Frédéric, Jos H. Beijnen, S. Barnett, et al.. (2023). Physiologically‐based pharmacokinetic model to predict doxorubicin and paclitaxel exposure in infants through breast milk. CPT Pharmacometrics & Systems Pharmacology. 12(12). 1931–1944.
6.
Bono, Johann S. de, Simon Lord, Christina Yap, et al.. (2023). 687P A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours. Annals of Oncology. 34. S479–S480.
7.
Kristeleit, Rebecca, Ruth Plummer, Robert H. Jones, et al.. (2023). A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British Journal of Cancer. 129(1). 38–45.
8.
Barnett, S., Victoria Holden, Quentin Campbell‐Hewson, & Gareth J. Veal. (2022). Perspectives and Expertise in Establishing a Therapeutic Drug Monitoring Programme for Challenging Childhood Cancer Patient Populations. Frontiers in Oncology. 11. 815040–815040.
9.
Menne, Tobias, Daniel Slade, Joshua Savage, et al.. (2022). Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial. BMJ Open. 12(3). e059872–e059872.
10.
Barnett, S., Arief Lalmohamed, Deborah A. Tweddle, et al.. (2021). Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance. European Journal of Cancer. 164. 137–154.
11.
Smith, Stuart, Betty Tyler, Gareth J. Veal, et al.. (2019). Overall Survival in Malignant Glioma Is Significantly Prolonged by Neurosurgical Delivery of Etoposide and Temozolomide from a Thermo-Responsive Biodegradable Paste. Clinical Cancer Research. 25(16). 5094–5106.
12.
Adamson, Peter C., Gareth J. Veal, Richard B. Womer, et al.. (2019). Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear‐medicine‐based estimates of renal function. Pediatric Blood & Cancer. 66(6). e27672–e27672.
13.
Chen, Lindi, Fabio Pastorino, Philip Berry, et al.. (2018). Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma. International Journal of Cancer. 144(12). 3146–3159.
14.
Thomas, Fabienne, Gareth J. Veal, Souleiman El Balkhi, et al.. (2018). Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemotherapy and Pharmacology. 82(2). 361–365.
15.
Irving, Julie, et al.. (2016). Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia. British Journal of Haematology. 173(1). 13–24.
16.
Widmer, Nicolas, Christophe Bardin, Étienne Chatelut, et al.. (2014). Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies. European Journal of Cancer. 50(12). 2020–2036.
17.
Veal, Gareth J., Julie Errington, Sophie E. Rowbotham, et al.. (2012). Adaptive Dosing Approaches to the Individualization of 13- Cis -Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma. Clinical Cancer Research. 19(2). 469–479.
18.
Boddy, Alan V., et al.. (2010). Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP‐glucuronosyltransferases. British Journal of Pharmacology. 162(4). 989–999.
19.
Veal, Gareth J., Sophie E. Rowbotham, & Alan V. Boddy. (2007). Pharmacokinetics and Pharmacogenetics of 13-cis-Retinoic Acid in the Treatment of Neuroblastoma. Therapies. 62(2). 91–93.
20.
Veal, Gareth J., Julie Errington, Caroline Ellershaw, Andrew Pearson, & Alan V. Boddy. (2005). A study to investigate the pharmacokinetics of carboplatin and etoposide in infants with neuroblastoma. Cancer Research. 65. 693–693.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by John M. Kovarik Breakdown of academic impact, for papers by Timothy W. Synold Breakdown of academic impact, for papers by Étienne Chatelut Breakdown of academic impact, for papers by Antonello Di Paolo Breakdown of academic impact, for papers by Massimo Zucchetti Breakdown of academic impact, for papers by Alan V. Boddy Breakdown of academic impact, for papers by Kristine R. Crews Breakdown of academic impact, for papers by Cristina Rodríguez‐Antona Breakdown of academic impact, for papers by Lalitha Iyer Breakdown of academic impact, for papers by Bruno Lacarelle